{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:14:58Z","timestamp":1770434098057,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2000,9,1]],"date-time":"2000-09-01T00:00:00Z","timestamp":967766400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2000,9]]},"DOI":"10.1007\/s11906-000-0027-x","type":"journal-article","created":{"date-parts":[[2007,5,24]],"date-time":"2007-05-24T05:53:31Z","timestamp":1179986011000},"page":"451-456","source":"Crossref","is-referenced-by-count":37,"title":["Spironolactone in congestive heart failure"],"prefix":"10.1007","volume":"2","author":[{"given":"Judith E.","family":"Soberman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl T.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"27_CR1","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.1016\/S0002-8703(98)70253-4","volume":"132","author":"M Gheorghiade","year":"1998","unstructured":"Gheorghiade M, Cody RJ, Francis GS, et al.: Current medical therapy for advanced heart failure. Am Heart J 1998, 132:S231-S248.","journal-title":"Am Heart J"},{"key":"27_CR2","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1016\/S0002-8703(98)70254-6","volume":"135","author":"CM O\u2018Connor","year":"1998","unstructured":"O\u2018Connor CM, Gattis WA, Swedberg K: Current and novel pharmacologic approaches in advanced heart failure. Am Heart J 1998, 135:S249-S263.","journal-title":"Am Heart J"},{"key":"27_CR3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709\u2013717. The RALES trial demonstrates a 30% reduction in total mortality among patients receiving low-dose spironolactone. This lower risk was attributed to both a reduction in progressive heart failure and sudden cardiac death. Hospitalization for worsening heart failure was also significantly decreased in the spironolactone group.","journal-title":"N Engl J Med"},{"key":"27_CR4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0008-6363(97)00091-6","volume":"35","author":"RJ MacFadyen","year":"1997","unstructured":"MacFadyen RJ, Barr CS, Struthers AD: Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997, 35:30\u201334. This article presents the first human data demonstrating that spironolactone, added to ACE inhibitor treatment, improves heart rate variability and reduces myocardial collagen turnover.","journal-title":"Cardiovasc Res"},{"key":"27_CR5","doi-asserted-by":"crossref","first-page":"34A","DOI":"10.1016\/0002-9149(93)90243-6","volume":"71","author":"F Zannad","year":"1993","unstructured":"Zannad F: Angiotensin-converting enzyme inhibitor and spironolactone combination therapy. New objectives in congestive heart failure treatment. Am J Cardiol 1993, 71:34A-39A.","journal-title":"Am J Cardiol"},{"key":"27_CR6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1210\/jcem-25-2-219","volume":"25","author":"JF Tait","year":"1965","unstructured":"Tait JF, Bougas J, Little B, et al.: Splanchnic extraction and clearance of aldosterone in subjects with minimal and marked cardiac dysfunction. J Clin Endocrinol 1965, 25:219\u2013228.","journal-title":"J Clin Endocrinol"},{"key":"27_CR7","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","volume":"82","author":"K Swedberg","year":"1990","unstructured":"Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990, 82:1730\u20131736.","journal-title":"Circulation"},{"key":"27_CR8","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/0735-1097(93)90095-I","volume":"21","author":"EJ Eichhorn","year":"1993","unstructured":"Eichhorn EJ, Tandon PK, DiBianco R, et al.: Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE Study. J Am Coll Cardiol 1993, 21:634\u2013640.","journal-title":"J Am Coll Cardiol"},{"key":"27_CR9","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/0002-9149(94)90362-X","volume":"74","author":"H Tsuji","year":"1994","unstructured":"Tsuji H, Venditti FJ Jr, Evans JC, et al.: The association of levels of serum potassium and magnesium with ventricular premature complexes (the Framingham Heart Study). Am J Cardiol 1994, 74:232\u2013235.","journal-title":"Am J Cardiol"},{"key":"27_CR10","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0735-1097(10)80329-8","volume":"16","author":"SS Gottlieb","year":"1990","unstructured":"Gottlieb SS, Baruch L, Kukin ML, et al.: Prognostic importance of the serum magnesium concentration in patients with congestive heart failure. J Am Coll Cardiol 1990, 16:827\u2013831.","journal-title":"J Am Coll Cardiol"},{"key":"27_CR11","first-page":"659","volume":"9","author":"AD Struthers","year":"1995","unstructured":"Struthers AD: Two new culprits in cardiovascular disease: QT dispersion and aldosterone. J Hum Hypertens 1995, 9:659\u2013661.","journal-title":"J Hum Hypertens"},{"key":"27_CR12","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0002-9149(99)80353-1","volume":"76","author":"CS Barr","year":"1995","unstructured":"Barr CS, Lang CC, Hanson J, et al.: Effects of adding Spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995, 76:1259\u20131265.","journal-title":"Am J Cardiol"},{"key":"27_CR13","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/cvr\/26.7.671","volume":"26","author":"CG Brilla","year":"1992","unstructured":"Brilla CG, Weber KT: Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 1992, 26:671\u2013677.","journal-title":"Cardiovasc Res"},{"key":"27_CR14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0008-6363(97)00097-7","volume":"35","author":"Y Sun","year":"1997","unstructured":"Sun Y, Ramires FJA, Weber KT: Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res 1997, 35:138\u2013147. Atrial and perivascular fibrosis of the great vessels was seen in response to angiotensin II or aldosterone independent of arterial hypertension or wall stress in an animal model.","journal-title":"Cardiovasc Res"},{"key":"27_CR15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1161\/01.HYP.24.1.30","volume":"24","author":"V Robert","year":"1994","unstructured":"Robert V, Van Thiem N, Cheav SL, et al.: Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension. Hypertension 1994, 24:30\u201336.","journal-title":"Hypertension"},{"key":"27_CR16","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0140-6736(94)91164-9","volume":"343","author":"CS Barr","year":"1994","unstructured":"Barr CS, Naas A, Freeman N, et al.: QT dispersion and sudden unexpected death in chronic heart failure. Lancet 1994, 343:327\u2013329.","journal-title":"Lancet"},{"key":"27_CR17","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1161\/01.HYP.19.3.270","volume":"19","author":"W Wang","year":"1992","unstructured":"Wang W, McClain JM, Zucker IH: Aldosterone reduces baroreceptor discharge in the dog. Hypertension 1992, 19:270\u2013277.","journal-title":"Hypertension"},{"key":"27_CR18","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.1365-2125.1999.00954.x","volume":"47","author":"AD Struthers","year":"1999","unstructured":"Struthers AD: Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure? Br J Clin Pharmacol 1999, 47:479\u2013482.","journal-title":"Br J Clin Pharmacol"},{"key":"27_CR19","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0146-2806(00)70011-9","volume":"25","author":"WH Frishman","year":"2000","unstructured":"Frishman WH: Recent advances in cardiovascular pharmacology. Curr Probl Cardiol 2000, 25:227\u2013295.","journal-title":"Curr Probl Cardiol"},{"key":"27_CR20","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","volume":"327","author":"MA Pfeffer","year":"1992","unstructured":"Pfeffer MA, Braunwald E, Moy LA, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992, 327:669\u2013677.","journal-title":"N Engl J Med"},{"issue":"5","key":"27_CR21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/00325481.1993.11701670","volume":"93","author":"KT Weber","year":"1993","unstructured":"Weber KT, Villarreal D: Role of aldosterone in congestive heart failure. Postgrad Med 1993, 93(5):203\u2013207.","journal-title":"Postgrad Med"},{"issue":"suppl N","key":"27_CR22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/eurheartj\/16.suppl_N.103","volume":"16","author":"AD Struthers","year":"1995","unstructured":"Struthers AD: Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J 1995, 16(suppl N):103\u2013106.","journal-title":"Eur Heart J"},{"key":"27_CR23","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/0002-9149(93)90986-M","volume":"72","author":"Y Bashir","year":"1993","unstructured":"Bashir Y, Sneddon JF, Staunton HA, et al.: Effects of long-term oral magnesium chloride replacement in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1993, 72:1156\u20131162.","journal-title":"Am J Cardiol"},{"key":"27_CR24","first-page":"471","volume-title":"Heart Disease: A Textbook of Cardiovascular Medicine","author":"RA Kelly","year":"1997","unstructured":"Kelly RA, Smith TW: Drugs used in the treatment of heart failure. In Heart Disease: A Textbook of Cardiovascular Medicine 5th edn. Edited by Braunwald E. Philadelphia: W. B. Saunders; 1997:471\u2013491.","edition":"5th edn"},{"issue":"2","key":"27_CR25","doi-asserted-by":"crossref","first-page":"I41","DOI":"10.1161\/01.HYP.5.2_Pt_2.I41","volume":"5","author":"MA Weber","year":"1983","unstructured":"Weber MA, Purdy RE, Drayer JI: Interactions of mineralocorticoids and pressor agents in vascular smooth muscle. Hypertension 1983, 5(2 pt 2):I41-I46.","journal-title":"Hypertension"},{"key":"27_CR26","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","volume":"101","author":"CAJ Farquharson","year":"2000","unstructured":"Farquharson CAJ, Struthers AD: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure. Circulation 2000, 101:594\u2013597. The use of spironolactone improves endothelial dysfunction in patients with CHF on ACE inhibitors.","journal-title":"Circulation"},{"key":"27_CR27","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1161\/01.RES.71.3.503","volume":"71","author":"M Lomb\u00e8s","year":"1992","unstructured":"Lomb\u00e8s M, Oblin M-E, Gasc J-M, et al.: Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 1992, 71:503\u2013510.","journal-title":"Circ Res"},{"key":"27_CR28","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1126\/science.2845584","volume":"242","author":"JW Funder","year":"1988","unstructured":"Funder JW, Pearce PT, Smith R, Smith AI: Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988, 242:583\u2013585.","journal-title":"Science"},{"key":"27_CR29","first-page":"395","volume":"122","author":"Y Sun","year":"1993","unstructured":"Sun Y, Ratajska A, Zhou G, Weber KT: Angiotensin converting enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterone. J Lab Clin Med 1993, 122:395\u2013403.","journal-title":"J Lab Clin Med"},{"key":"27_CR30","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/01.RES.67.6.1355","volume":"67","author":"CG Brilla","year":"1990","unstructured":"Brilla CG, Pick R, Tan LB, et al.: Remodeling of the rat right and left ventricle in experimental hypertension. Circ Res 1990, 67:1355\u20131364.","journal-title":"Circ Res"},{"key":"27_CR31","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3109\/08037059309077553","volume":"2","author":"SE Campbell","year":"1993","unstructured":"Campbell SE, Farb A, Weber KT: Pathologic remodeling of the myocardium in a weightlifter taking anabolic steroids. Blood Press 1993, 2:213\u2013216.","journal-title":"Blood Press"},{"key":"27_CR32","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1006\/jmcc.1993.1066","volume":"25","author":"CG Brilla","year":"1993","unstructured":"Brilla CG, Matsubara LS, Weber KT: Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993, 25:563\u2013575.","journal-title":"J Mol Cell Cardiol"},{"key":"27_CR33","first-page":"E657","volume":"269","author":"M Young","year":"1995","unstructured":"Young M, Head G, Funder J: Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995, 269:E657-E662.","journal-title":"Am J Physiol"},{"key":"27_CR34","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0002-9149(99)80686-9","volume":"75","author":"G Klappacher","year":"1995","unstructured":"Klappacher G, Franzen P, Haab D, et al.: Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 1995, 75:913\u2013918.","journal-title":"Am J Cardiol"},{"key":"27_CR35","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0002-9149(99)80251-3","volume":"76","author":"NB Host","year":"1995","unstructured":"Host NB, Jensen LT, Bendixen PM, et al.: The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction. Am J Cardiol 1995, 76:869\u2013873.","journal-title":"Am J Cardiol"},{"key":"27_CR36","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/0735-1097(94)90856-7","volume":"24","author":"DK Moser","year":"1994","unstructured":"Moser DK, Stevenson WG, Woo MA, Stevenson LW: Timing of sudden death in patients with heart failure. J Am Coll Cardiol 1994, 24:963\u2013967.","journal-title":"J Am Coll Cardiol"},{"key":"27_CR37","unstructured":"Physicians\u2018 Desk Reference. 53rd edn. Montvale, NJ: Medical Economics; 1999."},{"key":"27_CR38","doi-asserted-by":"crossref","unstructured":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987, 316:1429\u20131435.","DOI":"10.1056\/NEJM198706043162301"},{"key":"27_CR39","doi-asserted-by":"crossref","unstructured":"Effectiveness of spironolactone added to an angiotensinconverting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996, 78:902\u2013907.","DOI":"10.1016\/S0002-9149(96)00465-1"},{"issue":"suppl N","key":"27_CR40","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/eurheartj\/16.suppl_N.107","volume":"16","author":"D Pitt","year":"1995","unstructured":"Pitt D: ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES). Eur Heart J 1995, 16(suppl N):107\u2013110.","journal-title":"Eur Heart J"},{"key":"27_CR41","doi-asserted-by":"crossref","first-page":"586","DOI":"10.2165\/00003495-199447040-00003","volume":"47","author":"RJ Cody","year":"1994","unstructured":"Cody RJ: The clinical potential of renin inhibitors and angiotensin antagonists. Drugs 1994, 47:586\u2013598.","journal-title":"Drugs"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-000-0027-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-000-0027-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-000-0027-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:15:56Z","timestamp":1559434556000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-000-0027-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,9]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2000,9]]}},"alternative-id":["27"],"URL":"https:\/\/doi.org\/10.1007\/s11906-000-0027-x","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,9]]}}}